FISIOLOGÍA Y FARMACOLOGÍA
Departamento
Universidad del País Vasco/Euskal Herriko Unibertsitatea
Lejona, EspañaPublicaciones en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (21)
2023
-
Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
Cells, Vol. 12, Núm. 16
-
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108
-
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent
Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895
2022
-
TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation
Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004
-
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190
2021
-
Changes in the Objective Structured Clinical Examination (OSCE) of University Schools of Medicine during COVID-19. Experience with a computer-based case simulation OSCE (CCS-OSCE)
Revista Clinica Espanola, Vol. 221, Núm. 8, pp. 456-463
-
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma
Hepatology, Vol. 73, Núm. 6, pp. 2380-2396
-
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
Molecular Metabolism, Vol. 53
-
Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease
Hepatology, Vol. 73, Núm. 1, pp. 186-203
2020
-
Multi‐omics integration highlights the role of ubiquitination in ccl4‐induced liver fibrosis
International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-19
-
Opipramol inhibits lipolysis in human adipocytes without altering glucose uptake and differently from antipsychotic and antidepressant drugs with adverse effects on body weight control
Pharmaceuticals, Vol. 13, Núm. 3
2019
-
Cholangiocarcinoma: State-of-the-art knowledge and challenges
Liver International
-
Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib
British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800
2018
-
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344
-
MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation
Hepatology, Vol. 67, Núm. 4, pp. 1420-1440
2017
-
Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver
Journal of Lipid Research, Vol. 58, Núm. 9, pp. 1903-1915
2015
-
Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)
Journal of Controlled Release, Vol. 216, pp. 93-102
-
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease
Journal of Hepatology, Vol. 63, Núm. 4, pp. 952-961
2014
-
Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development
Molecular Cancer Research, Vol. 12, Núm. 1, pp. 91-100
-
SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling
Hepatology, Vol. 59, Núm. 5, pp. 1972-1983